

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2011; month=4; day=11; hr=13; min=31; sec=23; ms=954; ]

=====

Application No: 10591732 Version No: 1.0

Input Set:

Output Set:

Started: 2011-04-04 12:19:51.518  
Finished: 2011-04-04 12:19:52.085  
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 567 ms  
Total Warnings: 5  
Total Errors: 0  
No. of SeqIDs Defined: 5  
Actual SeqID Count: 5

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)

# SEQUENCE LISTING

<110> DAKE, MICHAEL D.  
WAUGH, JACOB M.

<120> COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND  
TRANSDERMAL DELIVERY OF BOTULINUM TOXINS

<130> 13720-105071US2

<140> 10591732

<141> 2011-04-04

<150> PCT/US05/07524

<151> 2005-03-03

<150> 60/550,015

<151> 2004-03-03

<160> 5

<170> PatentIn Ver. 3.5

<210> 1

<211> 45

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> misc\_feature

<222> (1)..(20)

<223> This region may encompass 0 to 20 "Gly" residues

<220>

<221> misc\_feature

<222> (21)..(45)

<223> This region may encompass 5, 7, 9, 11, 13, 15,  
17, 19, 21, 23 or 25 "Arg" residues

<220>

<223> see specification as filed for detailed description of  
substitutions and preferred embodiments

<400> 1

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly  
1 5 10 15

Gly Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg  
20 25 30

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg  
35 40 45

<210> 2  
<211> 51  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> This region may encompass 0 to 20 "Gly" residues

<220>  
<221> misc\_feature  
<222> (32)..(51)  
<223> This region may encompass 0 to 20 "Gly" residues

<220>  
<223> see specification as filed for detailed description of  
substitutions and preferred embodiments

<400> 2  
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly  
1 5 10 15

Gly Gly Gly Gly Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly  
20 25 30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly  
35 40 45

Gly Gly Gly  
50

<210> 3  
<211> 51  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> misc\_feature  
 <222> (1)..(20)  
 <223> This region may encompass 0 to 20 "Gly" residues  
  
 <220>  
 <221> misc\_feature  
 <222> (32)..(51)  
 <223> This region may encompass 0 to 20 "Gly" residues  
  
 <220>  
 <223> see specification as filed for detailed description of  
       substitutions and preferred embodiments  
  
 <400> 3  
 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly  
       1                  5                  10                  15  
  
 Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly  
           20                  25                  30  
  
 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly  
           35                  40                  45  
  
 Gly Gly Gly  
       50  
  
 <210> 4  
 <211> 49  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
       peptide  
  
 <220>  
 <221> misc\_feature  
 <222> (1)..(20)  
 <223> This region may encompass 0 to 20 "Gly" residues  
  
 <220>  
 <221> misc\_feature  
 <222> (30)..(49)  
 <223> This region may encompass 0 to 20 "Gly" residues  
  
 <220>  
 <223> see specification as filed for detailed description of  
       substitutions and preferred embodiments  
  
 <400> 4  
 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly  
       1                  5                  10                  15

Gly Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly  
20 25 30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly  
35 40 45

Gly

<210> 5

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 5

Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg  
1 5 10